Thinking beyond the tumor to better understand chronic symptoms in breast cancer survivors
- 159 Downloads
Over 200,000 women are diagnosed with breast cancer each year in the United States, and more than 80% are alive 10 years after diagnosis . Treatment generally includes surgery, radiation therapy, chemotherapy, and/or targeted therapies. Choice of treatment is determined by assessing the likely benefit of each therapy for an individual patient, taking into consideration tumor characteristics and likelihood of disease recurrence. Additional personalization of the treatment regimen is generally based on pre-existing patient comorbid conditions, such as heart failure or peripheral neuropathy, which can increase the potential risks of therapy.
Most long-term breast cancer survivors recover fully from treatment. However, a substantial proportion experience chronic symptoms, including pain and fatigue, which negatively impact quality of life . The etiology of these symptoms in patients that otherwise remain free from disease recurrence is unclear, especially since all patients...
KeywordsBreast Cancer Chronic Pain Fibromyalgia Breast Cancer Survivor Duloxetine
NLH is the Damon Runyon-Lilly Clinical Investigator supported (in part) by the Damon Runyon Cancer Research Foundation (CI-53-10).
NLH receives research funding from Eli Lilly, AstraZeneca, and Sanofi Aventis. DJC receives research funding from Forest Laboratories and Merck and is a consultant for Cypress Biosciences, Eli Lilly, Forest Laboratories, Jazz Pharmaceuticals, Merck, Pierre Fabre Pharmaceuticals USA, Pfizer, and UCB.
- 1.American Cancer Society: Breast Cancer Facts & Figures 2009–2010. http://www.cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts–figures-2009-2010. Accessed 25 Aug 2011
- 14.Galvan A, Fladvad T, Skorpen F, Gao X, Klepstad P, Kaasa S, Dragani TA (2011) Genetic clustering of European cancer patients indicates that opioid-mediated pain relief is independent of ancestry. Pharmacogenomics J. doi:10.1038/tpj.2011.27Google Scholar
- 17.Fernandez-de-Las-Penas C, Fernandez-Lao C, Cantarero-Villanueva I, Ambite-Quesada S, Rivas-Martinez I, del Moral-Avila R, Arroyo-Morales M (2011) Catechol-o-methyltransferase genotype (Val158Mmet) modulates cancer-related fatigue and pain sensitivity in breast cancer survivors. Breast Cancer Res Treat (in press)Google Scholar
- 27.Henry NL, Giles JT, Stearns V (2008) Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management. Oncology (Williston Park) 22:1401–1408Google Scholar
- 28.Crew KD, Capodice JL, Greenlee H, Brafman L, Fuentes D, Awad D, Yann Tsai W, Hershman DL (2010) Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol 28:1154–1160PubMedCrossRefGoogle Scholar
- 29.Henry NL, Banerjee M, Wicha M, Van Poznak C, Smerage JB, Schott AF, Griggs JJ, Hayes DF (2011) Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer. doi:10.1002/cncr.26230Google Scholar